Loading...
Loading...
India's rivaroxaban imports from UNITED STATES total $2.3M across 82 shipments from 15 foreign suppliers. M/S. ESPEE BIOPHARMA & FINCHEM LLC leads with $1.0M in import value; the top 5 suppliers together control 85.3% of this origin. Leading Indian buyers include RUBICON RESEARCH PRIVATE LIMITED. This corridor reflects India's pharmaceutical import demand for rivaroxaban — a diversified sourcing base with multiple active suppliers from UNITED STATES.

M/S. ESPEE BIOPHARMA & FINCHEM LLC is the leading Rivaroxaban supplier from UNITED STATES to India, with import value of $1.0M across 1 shipments. The top 5 suppliers — M/S. ESPEE BIOPHARMA & FINCHEM LLC, ESPEE BIOPHARMA & FINECHEM LLC, NEW LIFE MEDICALS (USA),INC., M/S. NEW LIFE MEDICALS(USA),INC, Espee Biopharma & Finechem LLC — collectively account for 85.3% of total import value from this origin.
Ranked by import value (USD) · Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | M/S. ESPEE BIOPHARMA & FINCHEM LLC | $1.0M | 1 | 42.9% |
| 2 | ESPEE BIOPHARMA & FINECHEM LLC | $767.8K | 18 | 32.8% |
| 3 | NEW LIFE MEDICALS (USA),INC. | $120.4K | 1 | 5.1% |
| 4 | M/S. NEW LIFE MEDICALS(USA),INC | $52.3K | 1 | 2.2% |
| 5 | Espee Biopharma & Finechem LLC | $50.9K | 3 | 2.2% |
| 6 | RAFF & HALL PHARMACY | $41.9K | 5 | 1.8% |
| 7 | AMSTERDAM PHARMA (APTEKA RX INC) | $34.6K | 3 | 1.5% |
| 8 | MAKS PHARMA AND DIAGNOSTICS INC | $30.4K | 3 | 1.3% |
| 9 | SSS PHARMACY INC | $30.1K | 1 | 1.3% |
| 10 | GOOD HEALTH PHARMA SUPPLIES | $29.5K | 6 | 1.3% |
| 11 | SUTPHIN DRUG INC. | $26.5K | 1 | 1.1% |
| 12 | PHARMACEUTICAL BUYERS INC | $25.6K | 1 | 1.1% |
| 13 | NEWLIFE MEDICALS USA INC | $22.4K | 4 | 1.0% |
| 14 | NEW LIFE MEDICALS LLC | $19.1K | 2 | 0.8% |
| 15 | SPRING BIO SOLUTION | $16.1K | 3 | 0.7% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | RUBICON RESEARCH PRIVATE LIMITED | $1.0M | 2 | 42.9% |
| 2 | LUPIN LIMITED | $570.8K | 5 | 24.4% |
| 3 | UMEDICA LABORATORIES PRIVATE LIMITED | $150.5K | 2 | 6.4% |
| 4 | TORRENT PHARMACEUTICALS LTD | $136.7K | 2 | 5.8% |
| 5 | INDOCO REMEDIES LIMITED | $57.7K | 4 | 2.5% |
| 6 | HETERO LABS LIMITED | $53.3K | 7 | 2.3% |
| 7 | MEDLEY PHARMACEUTICALS LIMITED | $46.2K | 7 | 2.0% |
| 8 | HETERO LABS LIMITED | $41.5K | 1 | 1.8% |
| 9 | AJANTA PHARMA LIMITED | $36.9K | 6 | 1.6% |
| 10 | ALKEM LABORATORIES LIMITED | $33.3K | 3 | 1.4% |
| 11 | TORRENT PHARMACEUTICALS LIMITED | $30.4K | 3 | 1.3% |
| 12 | WATSON PHARMA PRIVATE LIMITED | $27.1K | 2 | 1.2% |
| 13 | ALEMBIC PHARMACEUTICALS LIMITED | $20.1K | 3 | 0.9% |
| 14 | AIZANT DRUG RESEARCH SOLUTIONS PRIVATE LIMITED | $18.9K | 4 | 0.8% |
| 15 | MANKIND PHARMA LTD | $18.0K | 3 | 0.8% |
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Rivaroxaban suppliers from UNITED STATES to India include M/S. ESPEE BIOPHARMA & FINCHEM LLC, ESPEE BIOPHARMA & FINECHEM LLC, NEW LIFE MEDICALS (USA),INC.. The leading supplier is M/S. ESPEE BIOPHARMA & FINCHEM LLC with import value of $1.0M USD across 1 shipments. India imported Rivaroxaban worth $2.3M USD from UNITED STATES in total across 82 shipments.
India imported Rivaroxaban worth $2.3M USD from UNITED STATES across 82 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Rivaroxaban sourced from UNITED STATES include RUBICON RESEARCH PRIVATE LIMITED, LUPIN LIMITED, UMEDICA LABORATORIES PRIVATE LIMITED. The largest buyer is RUBICON RESEARCH PRIVATE LIMITED with $1.0M in imports across 2 shipments.
The total value of Rivaroxaban imports from UNITED STATES to India is $2.3M USD, across 82 shipments and 15 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
82 Verified Shipments
15 suppliers, 15 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists